Investors In People Recognition For Cyclacel

DUNDEE - 31 January 2001 - Cyclacel Limited, the UK-based cancer therapeutics company, today announced it has achieved Investors in People recognition from Investors In People (Scotland).

Spiro Rombotis, Chief Executive said: "Cyclacel's most valuable assets are its people. As a young company in the fast moving and globally competitive field of cancer drug discovery, we are committed to principles of best practice in our employment policies. IiP accreditation endorses our core values of caring for individual growth and encouraging the career and professional development of all colleagues. It also communicates these values to our families, friends, future employees, advisors and collaborators."

John Gardner, Investment Manager, Scottish Enterprise Tayside said, "Cyclacel's employees are to be congratulated on achieving Investors in People status. The company's progress has seen it double in size in a short period of time. Despite this rapid growth the IiP assessor's report clearly demonstrated that Cyclacel has remained committed to employee development and to ensuring good communication exists within the business which will in turn, form a sound foundation for future growth."

Cyclacel became operational in late 1997. It now employs 53 people at both its purpose-built laboratories in Dundee and its Polgen laboratory based in Cambridge.